LU91290I2 - Céfovécine, optionnellement sous la forme d'un sel, dont le sel de sodium (CONVENIAr) - Google Patents
Céfovécine, optionnellement sous la forme d'un sel, dont le sel de sodium (CONVENIAr)Info
- Publication number
- LU91290I2 LU91290I2 LU91290C LU91290C LU91290I2 LU 91290 I2 LU91290 I2 LU 91290I2 LU 91290 C LU91290 C LU 91290C LU 91290 C LU91290 C LU 91290C LU 91290 I2 LU91290 I2 LU 91290I2
- Authority
- LU
- Luxembourg
- Prior art keywords
- salt
- conveniar
- cefovecine
- optionally
- including sodium
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D463/00—Heterocyclic compounds containing 1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D463/10—Heterocyclic compounds containing 1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
- C07D463/14—Heterocyclic compounds containing 1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hetero atoms directly attached in position 7
- C07D463/16—Nitrogen atoms
- C07D463/18—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof
- C07D463/20—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof with the acylating radicals further substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D463/22—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof with the acylating radicals further substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen further substituted by nitrogen atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cephalosporin Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB909016189A GB9016189D0 (en) | 1990-07-24 | 1990-07-24 | Novel compounds |
| GB919109540A GB9109540D0 (en) | 1991-05-02 | 1991-05-02 | Novel compounds |
| PCT/GB1991/001228 WO1992001696A1 (fr) | 1990-07-24 | 1991-07-22 | Cephalosporines et homologues, preparations et compositions pharmaceutiques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LU91290I2 true LU91290I2 (fr) | 2007-01-22 |
Family
ID=26297372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU91290C LU91290I2 (fr) | 1990-07-24 | 2006-11-22 | Céfovécine, optionnellement sous la forme d'un sel, dont le sel de sodium (CONVENIAr) |
Country Status (26)
| Country | Link |
|---|---|
| EP (2) | EP0540606A1 (fr) |
| JP (2) | JPH05509089A (fr) |
| KR (1) | KR100189075B1 (fr) |
| CN (2) | CN1061046C (fr) |
| AP (1) | AP832A (fr) |
| AT (1) | ATE185567T1 (fr) |
| AU (1) | AU648329B2 (fr) |
| CA (2) | CA2087967C (fr) |
| CZ (1) | CZ6493A3 (fr) |
| DE (2) | DE69131714T2 (fr) |
| DK (1) | DK0540609T3 (fr) |
| ES (1) | ES2137162T3 (fr) |
| FI (1) | FI930270L (fr) |
| GR (1) | GR3031711T3 (fr) |
| HU (1) | HUT63628A (fr) |
| IE (1) | IE912569A1 (fr) |
| IL (1) | IL98909A0 (fr) |
| LU (1) | LU91290I2 (fr) |
| MX (1) | MX9100317A (fr) |
| MY (1) | MY106399A (fr) |
| NL (1) | NL300249I1 (fr) |
| NO (1) | NO930226L (fr) |
| NZ (1) | NZ239061A (fr) |
| PT (1) | PT98426A (fr) |
| WO (2) | WO1992001696A1 (fr) |
| YU (1) | YU129691A (fr) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9125645D0 (en) * | 1991-12-03 | 1992-01-29 | Smithkline Beecham Plc | Novel compounds |
| EP0624160B1 (fr) * | 1992-01-22 | 2001-10-31 | Pfizer Inc. | Derives de 2-isocephem et d'oxacephem, procedes de preparation, les intermediaires de ceux-ci et leur utilisation comme agents antibacteriens |
| GB9212609D0 (en) * | 1992-06-13 | 1992-07-29 | Smithkline Beecham Plc | Novel compounds |
| GB9213567D0 (en) * | 1992-06-26 | 1992-08-12 | Smithkline Beecham Plc | Novel compounds |
| GB9424847D0 (en) * | 1994-12-09 | 1995-02-08 | Smithkline Beecham Plc | Novel process |
| GB2300856A (en) * | 1995-05-16 | 1996-11-20 | Pfizer Ltd | Beta-lactam preparation |
| WO1998014421A1 (fr) * | 1996-10-02 | 1998-04-09 | Daiichi Pharmaceutical Co., Ltd. | Procede d'esterification de composes carboxyliques |
| FR2776292B1 (fr) | 1998-03-20 | 2004-09-10 | Oncopharm | Cephalotaxanes porteurs de chaine laterale et leur procede de synthese |
| GB0019124D0 (en) * | 2000-08-03 | 2000-09-27 | Pfizer | Novel process |
| RU2237670C1 (ru) * | 2000-12-04 | 2004-10-10 | Пфайзер Продактс Инк. | Способ взаимодействия и промежуточные продукты, пригодные для получения цефалоспоринов |
| BR0115872A (pt) * | 2000-12-04 | 2003-10-28 | Pfizer Prod Inc | Processo e derivados de éster úteis para a preparação de cefalosporinas |
| US7378408B2 (en) * | 2001-11-30 | 2008-05-27 | Pfizer Inc. | Methods of treatment and formulations of cephalosporin |
| KR100710555B1 (ko) | 2001-12-04 | 2007-04-24 | 에스케이 주식회사 | 광학적으로 순수한 (r)-폼 또는 (s)-폼의테트라히드로퓨라닐 케톤의 제조방법 |
| SI2794627T1 (sl) | 2011-12-22 | 2019-02-28 | Alios Biopharma, Inc. | Substituirani nukleozidi, nukleotidi in njihovi analogi |
| USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| PL2861611T3 (pl) | 2012-05-25 | 2017-08-31 | Janssen Sciences Ireland Uc | Nukleozydy uracylowe spirooksetanu |
| ES2865402T3 (es) | 2012-12-21 | 2021-10-15 | Janssen Biopharma Inc | 4'-fluoronucleósidos, 4'-fluoronucleótidos y análogos de los mismos para el tratamiento del VHC |
| CN105254648B (zh) * | 2015-11-13 | 2018-04-03 | 广东温氏大华农生物科技有限公司 | 一种头孢维星及其钠盐的合成方法 |
| GB2575261B (en) | 2018-07-02 | 2022-03-09 | Norbrook Lab Ltd | Intermediates in the synthesis of C3-substituted cephalosporins |
| AU2019324170A1 (en) | 2018-08-23 | 2021-02-18 | Seagen, Inc. | Anti-TIGIT antibodies |
| CR20220316A (es) | 2019-12-06 | 2022-10-07 | Vertex Pharma | Tetrahidrofuranos sustituidos como moduladores de canales de sodio |
| TWI775313B (zh) | 2020-02-18 | 2022-08-21 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| TWI883391B (zh) | 2020-02-18 | 2025-05-11 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| AU2021224588B2 (en) | 2020-02-18 | 2024-07-18 | Gilead Sciences, Inc. | Antiviral compounds |
| CN114213433B (zh) * | 2020-06-08 | 2023-03-24 | 重庆医药高等专科学校 | C-3位四氢呋喃取代的头孢菌素-铁载体耦合物的制备方法 |
| KR20230170745A (ko) | 2021-04-16 | 2023-12-19 | 길리애드 사이언시즈, 인코포레이티드 | 아미드를 사용한 카르바뉴클레오시드를 제조하는 방법 |
| JP2024522292A (ja) | 2021-06-04 | 2024-06-13 | バーテックス ファーマシューティカルズ インコーポレイテッド | ナトリウムチャネルのモジュレーターとしてのn-(ヒドロキシアルキル(ヘテロ)アリール)テトラヒドロフランカルボキサミド |
| US12116380B2 (en) | 2021-08-18 | 2024-10-15 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2197573A1 (en) * | 1972-09-07 | 1974-03-29 | Roussel Uclaf | 7-substd-phenylacetamido-cephalosporin derivs - - antibiotics active against streptococci and staphylococci |
| BE793448A (fr) * | 1971-12-31 | 1973-06-28 | Roussel Uclaf | Procede de preparation de nouveaux derives des cephalosporines et produits obtenus |
| BE791160A (fr) * | 1972-01-03 | 1973-05-09 | Beecham Group Ltd | Nouveaux cephemes substitues |
| BE791161A (fr) * | 1972-01-03 | 1973-05-09 | Beecham Group Ltd | Procede pour la preparation d'analogues des cephalosporines |
| NL7305936A (fr) * | 1972-05-05 | 1973-11-07 | ||
| JPS5849382A (ja) * | 1981-09-18 | 1983-03-23 | Kyowa Hakko Kogyo Co Ltd | β−ラクタム化合物 |
| GB8821797D0 (en) * | 1988-09-16 | 1988-10-19 | Beecham Group Plc | Novel compounds |
| ATE171705T1 (de) * | 1989-03-30 | 1998-10-15 | Pfizer | Cephalosporine und ihre homologen, verfahren zu ihrer herstellung und pharmazeutische präparate |
-
1991
- 1991-07-16 MY MYPI91001321A patent/MY106399A/en unknown
- 1991-07-22 MX MX9100317A patent/MX9100317A/es unknown
- 1991-07-22 DE DE69131714T patent/DE69131714T2/de not_active Expired - Lifetime
- 1991-07-22 WO PCT/GB1991/001228 patent/WO1992001696A1/fr not_active Ceased
- 1991-07-22 FI FI930270A patent/FI930270L/fi unknown
- 1991-07-22 JP JP3512255A patent/JPH05509089A/ja active Pending
- 1991-07-22 NZ NZ239061A patent/NZ239061A/en not_active IP Right Cessation
- 1991-07-22 EP EP91913545A patent/EP0540606A1/fr not_active Withdrawn
- 1991-07-22 CZ CS9364A patent/CZ6493A3/cs unknown
- 1991-07-22 DK DK91913583T patent/DK0540609T3/da active
- 1991-07-22 JP JP3512368A patent/JP2851428B2/ja not_active Expired - Lifetime
- 1991-07-22 AT AT91913583T patent/ATE185567T1/de active
- 1991-07-22 AP APAP/P/1991/000305A patent/AP832A/en active
- 1991-07-22 EP EP91913583A patent/EP0540609B1/fr not_active Expired - Lifetime
- 1991-07-22 AU AU82224/91A patent/AU648329B2/en not_active Expired
- 1991-07-22 DE DE200612000065 patent/DE122006000065I2/de active Active
- 1991-07-22 IL IL98909A patent/IL98909A0/xx unknown
- 1991-07-22 HU HU93177A patent/HUT63628A/hu unknown
- 1991-07-22 CA CA002087967A patent/CA2087967C/fr not_active Expired - Lifetime
- 1991-07-22 WO PCT/GB1991/001227 patent/WO1992001695A1/fr not_active Ceased
- 1991-07-22 IE IE256991A patent/IE912569A1/en not_active IP Right Cessation
- 1991-07-22 KR KR1019930700216A patent/KR100189075B1/ko not_active Expired - Lifetime
- 1991-07-22 CA CA002359744A patent/CA2359744C/fr not_active Expired - Lifetime
- 1991-07-22 ES ES91913583T patent/ES2137162T3/es not_active Expired - Lifetime
- 1991-07-23 YU YU129691A patent/YU129691A/sh unknown
- 1991-07-23 PT PT98426A patent/PT98426A/pt not_active Application Discontinuation
- 1991-07-24 CN CN91105783A patent/CN1061046C/zh not_active Expired - Lifetime
-
1993
- 1993-01-22 NO NO93930226A patent/NO930226L/no unknown
-
1998
- 1998-11-14 CN CN98122407A patent/CN1111410C/zh not_active Expired - Lifetime
-
1999
- 1999-11-03 GR GR990402803T patent/GR3031711T3/el unknown
-
2006
- 2006-11-22 LU LU91290C patent/LU91290I2/fr unknown
- 2006-11-27 NL NL300249C patent/NL300249I1/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LU91290I2 (fr) | Céfovécine, optionnellement sous la forme d'un sel, dont le sel de sodium (CONVENIAr) | |
| LU88809I2 (fr) | Lamivudine facultativement sous la forme d'un sel pharmaceutiquement acceptable | |
| LU90468I2 (fr) | Zanamivir facultativement sous la forme d'un sel ou d'un derive pharmaceutiquement acceptable | |
| LU88842I2 (fr) | Nebivolol optionnellement sous forme d'un sel ou d'un hydrate pharmaceutiquement acceptable en particulier hydroclorure de Nebivolol | |
| LU91306I2 (fr) | Mitratapide, optionnellement sous forme d'un sel d'addition acide pharmaceutiquement acceptable (YARVITAN) | |
| LU92428I2 (fr) | Bosutinib, éventuellement sous la forme d'un sel pharmaceutiquement acceptable | |
| LU90593I2 (fr) | Quetiapine facutativement sous forme d'un sel pharmaceutiquement acceptabe | |
| LU91372I2 (fr) | Retapamulin optionnellement sous forme d'un sel pharmaceutiquement acceptable (altargo) | |
| LU91442I2 (fr) | "Varénicline, optionnellement sous forme d'un sel pharmaceutiquement acceptable, y compris le sel tartrate" | |
| EP0644809A4 (fr) | Technique d'impression tridimensionnelle. | |
| YU58190A (en) | Aminoacid's derivatives | |
| NO912036D0 (no) | Blekepreparat. | |
| OA09323A (en) | "Imadazo /4, 5-b/ quinolinyloxyalkanoic acid amides with enhanced water solubility". | |
| LU88746I2 (fr) | Valaciclovir facultativement sous la forme d'un sel pharmaceutiquement acceptable y compris le sel d'addition de l'acide chlorhydrique | |
| IT8722420A0 (it) | Microemulsioni acquose comprendenti perfluoropolieteri funzionali. | |
| EP0525106A4 (en) | 2',3'-dideoxy-4'-thioribonucleosides as antiviral agents | |
| DE3775802D1 (de) | 2-(4'-alkoxyphenyl)-5-alkylpyridine. | |
| OA09328A (en) | "Heterocyclic compounds". | |
| IT212017Z2 (it) | Cerotto, in particolare perl'impiego in corrispondenza di zone articolari. | |
| ES512344A0 (es) | "procedimiento para la preparacion continua, en una etapa, de granulados de cloruro de magnesio". | |
| IT9011313U1 (it) | Cucchiaio prendi-olive in salamoia detto "prendi-olive". | |
| EP0415556A3 (en) | Water soluble 1,2-dithio-3-thiones | |
| MA21815A1 (fr) | Capsule "s" . | |
| IT8919287A0 (it) | Stampo per la colata di getti nonche' suo impiego. | |
| CS597589A2 (en) | Even linen's single-cover press-iron |